Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation

Front Immunol. 2022 Sep 23:13:971156. doi: 10.3389/fimmu.2022.971156. eCollection 2022.

Abstract

Cytomegalovirus (CMV) infection remains a frequent complication after hematopoietic stem cell transplantation (HSCT) and causes significant morbidity and mortality in transplantation recipients. In this review, we highlight the role of major risk factors that are associated with the incidence of CMV infection. Advances in immunosurveillance may predict CMV infection, allowing early interventions to prevent severe infection. Furthermore, numerous therapeutic strategies against CMV infection after HSCT are summarized. A comprehensive understanding of the current situation of CMV treatment may provide a hint for clinical practice and even promote the development of novel strategies for precision medicine.

Keywords: CMV; HSCT; diagnosis; immune recovery; treatment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytomegalovirus
  • Cytomegalovirus Infections* / diagnosis
  • Cytomegalovirus Infections* / etiology
  • Cytomegalovirus Infections* / prevention & control
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Transplant Recipients
  • Transplantation, Homologous / adverse effects